Stonnington Group, LLC Apellis Pharmaceuticals, Inc. Transaction History
Stonnington Group, LLC
- $381 Million
- Q1 2023
A detailed history of Stonnington Group, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Stonnington Group, LLC holds 9,400 shares of APLS stock, worth $226,164. This represents 0.16% of its overall portfolio holdings.
Number of Shares
9,400Holding current value
$226,164% of portfolio
0.16%Shares
6 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
123MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$294 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$286 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$284 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$242 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$232 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.64B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...